Hainan Province Approves Heart-Lung Walking Test Analysis Software as Category II Device
The Hainan Medical Products Administration has granted marketing approval to a heart-lung walking test data...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Longbio Pharma Secures RMB 100 Million in Series B2 Financing to Advance Clinical Programs
Longbio Pharma, a biopharmaceutical company specializing in biomacromolecule drug development and based in Shanghai, China,...
Yunnan Province Increases Pediatric Medical Service Prices for Children Under 6
The Yunnan Provincial Healthcare Security Administration and the Health Commission of Yunnan Province have issued...
Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released...
Global Researchers Call for the Revival of the Human Genome Project to Advance Precision Medicine
A consortium of international researchers, spearheaded by a team from China’s gene sequencing giant BGI,...
Sanofi’s Sarclisa Secures FDA Approval for First-Line Multiple Myeloma Treatment
Sanofi (EPA: SAN; NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA)...
Novo Nordisk’s Obesity Drug Monlunabant Phase IIa Results Lead to Share Price Drop
Novo Nordisk (NYSE: NVO), a Danish pharmaceutical company, has reported Phase IIa trial results for...
Janssen and Yuhan Halt Development of Next-Gen EGFR Inhibitor for NSCLC
Yuhan, a South Korean pharmaceutical company, and its partner Janssen Biotech, a subsidiary of US...
Sichuan Biokin’s Multi-Specific Antibody GNC-077 Gets NMPA Nod for Advanced Solid Tumor Clinical Trial
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a biopharmaceutical company based in China, has announced...
SciClone Pharmaceuticals Gets NMPA Approval for Phase III Study of First-in-Class SERD Orserdu
SciClone Pharmaceuticals Inc. (HKG: 6600), a Chinese pharmaceutical company, has received approval from the National...
ApolloBio’s HPV Therapeutic Vaccine VGX-3100 Gets NMPA Green Light for Clinical Trial
ApolloBio Corp., a joint stock company of China’s leading cephalosporin manufacturer Jincheng Pharmaceutical Group Co.,...
Jacobio Pharma’s Pan-KRAS Inhibitor JAB-23E73 Clears FDA Hurdle for Clinical Trials
Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received the green light...
Hybribio’s Chloroquine Phosphate Gel Cleared for Clinical Trial on High-Risk HPV Infections
Hybribio Limited (SHE: 300639), a Guangdong-based pharmaceutical company, has received approval from the National Medical...
Ocumension Therapeutics’ OT-502 Receives NMPA Acceptance for Post-Cataract Inflammation Treatment
Ocumension Therapeutics (HKG: 1477) announced on September 23, 2024, that the National Medical Products Administration...
Yantai Dongcheng Pharmaceutical’s 18F-LNC1007 Receives Clinical Clearance for Solid Tumor Diagnostics
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received clinical...
Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in...
Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives
We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing...
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System
Beijing is set to follow in the footsteps of Boao Lecheng with the release of...